Revenue reached $356.0M in 2026Q3 with an operating margin of 50.8%, but quarterly profitability has been volatile, with operating margin ranging from 23.2% to -31.4% over the past ten quarters.
Supernus Pharmaceuticals, Inc. (SUPN) annual income statement — 18-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|
| Sales/Revenue | 1.37B | 1.24B | 1.19B | 1.09B | 901M | 791M | 647M | 785M | 959.92M | 1.15B | 968.89M | 144.43M | 122.05M | 12.02M | 1.48M | 803K | 106K | 37.92M | 8.89M |
| Revenue Growth % | 16.34% | 4.29% | 8.69% | 21.31% | 13.91% | 22.26% | -17.58% | -18.22% | -16.39% | 18.5% | 570.85% | 18.34% | 915.43% | 712.09% | 84.31% | 657.55% | -99.72% | 326.65% | - |
| Cost of Goods Sold | 204M | 246M | 231M | 174M | 151M | 127M | 97M | 140M | 134.68M | 122.9M | 110.81M | 8.42M | 5.76M | 1.1M | 0 | 0 | -13.4M | -8.59M | 336 |
| COGS % of Revenue | - | 19.85% | 19.44% | 15.92% | 16.76% | 16.06% | 14.99% | 17.83% | 14.03% | 10.7% | 11.44% | 5.83% | 4.72% | 9.19% | - | - | -12645.28% | -22.65% | 0% |
| Gross Profit | 1.17B | 993M | 957M | 919M | 750M | 664M | 550M | 645M | 825.25M | 1.03B | 858.08M | 136M | 116.29M | 10.91M | 1.48M | 803K | 13.51M | 46.51M | 8.89M |
| Gross Margin % | 85.15% | 80.15% | 80.56% | 84.08% | 83.24% | 83.94% | 85.01% | 82.17% | 85.97% | 89.3% | 88.56% | 94.17% | 95.28% | 90.81% | 100% | 100% | 12745.28% | 122.65% | 100% |
| Gross Profit Growth % | - | 3.76% | 4.13% | 22.53% | 12.95% | 20.73% | -14.73% | -21.84% | -19.5% | 19.48% | 530.92% | 16.96% | 965.39% | 637.5% | 84.31% | -94.06% | -70.95% | 423.29% | - |
| Operating Expenses | 570M | 728M | 925M | 1.07B | 831M | 451M | 706M | 467M | 508.14M | 601.89M | 520.16M | 118.34M | 92.06M | 72.83M | 43.65M | 38.55M | 40.23M | 33.91M | 34.75M |
| OpEx % of Revenue | - | 58.76% | 77.86% | 98.35% | 92.23% | 57.02% | 109.12% | 59.49% | 52.94% | 52.42% | 53.69% | 81.94% | 75.43% | 606% | 2949.26% | 4801.37% | 37951.89% | 89.41% | 390.93% |
| Selling, General & Admin | 520M | 634M | 618M | 569M | 469M | 431M | 649M | 395M | 444.14M | 508.4M | 411.18M | 89.2M | 72.47M | 55.59M | 20.13M | 7.93M | 5.08M | 4.65M | 4.29M |
| SG&A % of Revenue | - | 51.17% | 52.02% | 52.06% | 52.05% | 54.49% | 100.31% | 50.32% | 46.27% | 44.28% | 42.44% | 61.76% | 59.38% | 462.52% | 1360.27% | 987.3% | 4792.45% | 12.26% | 48.23% |
| Research & Development | 50M | 97M | 107M | 116M | 74M | 52M | 40M | 53M | 63.99M | 93.49M | 108.98M | 29.14M | 19.59M | 17.25M | 23.52M | 30.63M | 35.15M | 29.26M | 30.46M |
| R&D % of Revenue | - | 7.83% | 9.01% | 10.61% | 8.21% | 6.57% | 6.18% | 6.75% | 6.67% | 8.14% | 11.25% | 20.17% | 16.05% | 143.48% | 1588.99% | 3814.07% | 33159.43% | 77.15% | 342.7% |
| Other Operating Expenses | 0 | -3M | 200M | 390M | 288M | -32M | 17M | 19M | 0 | 0 | 0 | 38K | 39K | 101K | 0 | 117K | 542K | 0 | 0 |
| Operating Income | 600M | 265M | 32M | -156M | -81M | 213M | -156M | 178M | 317.11M | 423.32M | 337.92M | 17.66M | 24.23M | -61.92M | -42.17M | -37.75M | -40.12M | 4.02M | -25.86M |
| Operating Margin % | 43.67% | 21.39% | 2.69% | -14.27% | -8.99% | 26.93% | -24.11% | 22.68% | 33.03% | 36.87% | 34.88% | 12.23% | 19.85% | -515.18% | -2849.26% | -4701.37% | -37851.89% | 10.59% | -290.93% |
| Operating Income Growth % | - | 728.13% | 120.51% | -92.59% | -138.03% | 236.54% | -187.64% | -43.87% | -25.09% | 25.27% | 1812.93% | -27.09% | 139.13% | -46.84% | -11.7% | 5.91% | -1099.08% | 115.53% | - |
| EBITDA | 613M | 285M | 60M | -141M | -65M | 235M | -130M | 206M | 333.11M | 436.32M | 351.92M | 18.59M | 25.16M | -61.18M | -41.3M | -36.87M | -38.94M | 5.09M | -24.75M |
| EBITDA Margin % | 44.61% | 23% | 5.05% | -12.9% | -7.21% | 29.71% | -20.09% | 26.24% | 34.7% | 38% | 36.32% | 12.87% | 20.61% | -509.01% | -2790.41% | -4591.91% | -36731.13% | 13.42% | -278.39% |
| EBITDA Growth % | 73.65% | 375% | 142.55% | -116.92% | -127.66% | 280.77% | -163.11% | -38.16% | -23.65% | 23.98% | 1793.47% | -26.12% | 141.12% | -48.14% | -12% | 5.3% | -865.23% | 120.56% | - |
| D&A (Non-Cash Add-back) | 13M | 20M | 28M | 15M | 16M | 22M | 26M | 28M | 16M | 13M | 14M | 921K | 928K | 742K | 871K | 879K | 1.19M | 1.07M | 1.11M |
| EBIT | 555M | 284M | 55M | -114M | -62M | 216M | -149M | 202M | 295.14M | 193M | 136.45M | 20.84M | 24.83M | -84.42M | -42.71M | -37.6M | -39.47M | 4.14M | -24.8M |
| Net Interest Income | -1M | -23M | -18M | 8M | -10M | -22M | -17M | 2M | -14M | -42M | -51M | -4.09M | -5.27M | -7.55M | -3.46M | -1.83M | 107K | 122K | -7.62M |
| Interest Income | 16M | 22M | 23M | 43M | 19M | 4M | 7M | 24M | 17M | 7M | 0 | 681K | 348K | 299K | 120K | 31K | 107K | 122K | 1.06M |
| Interest Expense | 17M | 45M | 41M | 35M | 29M | 26M | 24M | 22M | 31M | 49M | 51M | 4.77M | 5.62M | 7.85M | 3.58M | 1.87M | 0 | 0 | 8.68M |
| Other Income/Expense | -62M | -26M | -18M | 7M | -8M | -23M | -17M | 2M | -14M | -56M | -51M | -6.23M | -4.36M | -30.35M | -4.12M | -1.72M | 649K | 122K | -7.62M |
| Pretax Income | 538M | 239M | 14M | -149M | -89M | 190M | -173M | 180M | 265.53M | 143.91M | 89.75M | 14.97M | 19.87M | -92.27M | -46.28M | -39.47M | -39.47M | 4.14M | -33.48M |
| Pretax Margin % | 39.16% | 19.29% | 1.18% | -13.63% | -9.88% | 24.02% | -26.74% | 22.93% | 27.66% | 12.53% | 9.26% | 10.37% | 16.28% | -767.73% | -3127.3% | -4915.32% | -37239.62% | 10.91% | -376.67% |
| Income Tax | 88M | 29M | 11M | -20M | -44M | -15M | -25M | 46M | 2.87M | 82.98M | 57.69M | 956K | 0 | 0 | 0 | -16.25M | -399K | 0 | 0 |
| Effective Tax Rate % | 16.36% | 12.13% | 78.57% | 13.42% | 49.44% | -7.89% | 14.45% | 25.56% | 1.08% | 57.66% | 64.29% | 6.39% | 0% | 0% | 0% | 41.16% | 1.01% | 0% | 0% |
| Net Income | 450M | 210M | 2M | -129M | -44M | 205M | -148M | 134M | 262.67M | 60.92M | 32.05M | 14.02M | 19.87M | -92.27M | -46.28M | 56M | -38.46M | 460K | -33.48M |
| Net Margin % | 32.75% | 16.95% | 0.17% | -11.8% | -4.88% | 25.92% | -22.87% | 17.07% | 27.36% | 5.31% | 3.31% | 9.7% | 16.28% | -767.73% | -3127.3% | 6974.22% | -36285.85% | 1.21% | -376.67% |
| Net Income Growth % | 171.08% | 10400% | 101.55% | -193.18% | -121.46% | 238.51% | -210.45% | -48.98% | 331.14% | 90.08% | 128.68% | -29.47% | 121.53% | -99.36% | -182.65% | 245.6% | -8461.52% | 101.37% | - |
| Net Income (Continuing) | 450M | 210M | 3M | -129M | -45M | 205M | -148M | 134M | 262.67M | 60.92M | 32.05M | 13.94M | 19.87M | -92.27M | -46.28M | -23.23M | -39.08M | 4.14M | -33.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.19M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 3.69 | 1.64 | 0.02 | -0.91 | -0.37 | 1.31 | -1.08 | 0.92 | 1.75 | 0.41 | 0.22 | 0.28 | 0.32 | -2.90 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 |
| EPS Growth % | 175.38% | 10833.33% | 101.65% | -145.95% | -128.24% | 221.3% | -217.39% | -47.43% | 326.83% | 86.36% | -21.43% | -12.5% | 111.03% | -9.43% | -172.8% | 230.94% | -1223.81% | 91.32% | - |
| EPS (Basic) | - | 1.68 | 0.02 | -0.94 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 | 0.29 | 0.47 | -2.90 | -2.65 | 3.64 | -2.78 | -0.21 | -2.42 |
| Diluted Shares Outstanding | 122M | 128M | 133M | 141.8M | 139.01M | 154.23M | 146.57M | 151.07M | 150.23M | 149.7M | 148.64M | 51.16M | 50.58M | 31.85M | 17.44M | 13.86M | 13.86M | 13.86M | 13.86M |
| Basic Shares Outstanding | 118M | 125M | 132M | 137.31M | 139.01M | 145.66M | 146.57M | 146.05M | 145.43M | 144.23M | 143.97M | 47.49M | 42.26M | 31.82M | 17.44M | 13.86M | 13.86M | 13.86M | 13.86M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | 215.28% | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying SUPN stock.
For fiscal year 2025, Supernus Pharmaceuticals, Inc. (SUPN) reported total revenue of $1.24B. This represents a 13838.6% increase compared to $8.9M in 2008.
Supernus Pharmaceuticals, Inc. (SUPN) is profitable, generating $210.0M in net income for the fiscal year ending 2025 with a net profit margin of 16.9%.
Supernus Pharmaceuticals, Inc. (SUPN) reported an operating income of $265.0M, resulting in an operating profit margin of 21.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Supernus Pharmaceuticals, Inc. (SUPN) generated $993.0M in gross profit for the year, representing a gross profit margin of 80.1%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Volatile quarterly profitability
Metrics are mathematically derived from official filings.
Revenue Rebound Lacks Consistent Momentum
According to the supplied quarterly income statements, SUPN revenue rose from $149.8M in 2025Q1 to $356.0M in 2026Q3, yet growth rates have swung between negative and triple-digit percentages, signaling lumpy rather than durable expansion.
The jump to $356.0M in 2026Q3 against a 85.3% year-over-year gain is the single largest data point in the set and may reflect a one-time or lumpy contribution rather than a repeatable run rate. Sequential revenue was flat-to-down across 2026Q1 and 2026Q2, which suggests the top line depends heavily on specific product or licensing events. Investors should monitor whether the 2026Q3 level holds in subsequent quarters before extrapolating growth.
Gross Margins Hold Near Ninety Percent
As reported in the income statement history, SUPN gross margin has stayed between 84.6% and 90.1% across all ten quarters, indicating a high-margin product mix with limited cost-driven variability.
A consistently high gross margin points to a specialty pharmaceutical profile where cost of goods is a small share of revenue. The stability across both growth and contraction periods suggests pricing power has not been materially eroded. The margin level sits well above generic manufacturers but the data alone cannot confirm how much of it is structurally durable versus product-cycle dependent.
Operating Leverage Turns Sharply Volatile
Based on the reported figures, SUPN operating margin swung from 23.2% in 2024Q3 to -31.4% in 2025Q3, showing that fixed operating spend magnifies revenue swings in both directions.
Operating expenses have remained relatively elevated against revenue, so modest top-line shortfalls translate into outsized operating losses. The 2025Q3 and 2026Q2 operating losses coincided with spikes in SG&A relative to revenue, which suggests the cost base was not flexed down with sales. This operating leverage cuts both ways and warrants further investigation into the drivers of those expense peaks.
Net Income Tracks Operating Volatility Closely
According to the supplied EPS figures, SUPN diluted EPS ranged from -$1.01 to $1.12 over ten quarters, and net income moved in step with operating income rather than being buoyed by non-operating items.
Because net income broadly mirrors operating income, the earnings base does not appear to rely heavily on below-the-line gains, which is a constructive quality signal. Stock-based compensation remained in a relatively narrow band for most quarters, though the 2025Q4 SBC figure stands out and warrants checking against the filing. Earnings per share volatility of this magnitude makes trailing valuation ratios unreliable as a guide.
Quarterly Swings Challenge the Recovery Thesis
The strongest challenge to the income statement narrative is that SUPN has posted alternating profitable and loss-making quarters, with two sizable operating losses in the last five periods, which may undermine confidence in sustained profitability.
A bear case would argue that the 2026Q3 profit is an outlier against a pattern of repeated losses, including -$60.2M operating income in 2025Q3 and -$58.0M in 2026Q2. Peer comparisons show SUPN lagging on net margin relative to higher-margin peers such as ACAD and INVA, which suggests the cost structure may be less efficient. Whether the recent profitability proves durable is an open question the reported figures alone cannot resolve.